Overview

Sickness Evaluation at Altitude With Acetazolamide at Relative Dosages

Status:
Completed
Trial end date:
2018-09-30
Target enrollment:
Participant gender:
Summary
This double blind randomized trial will compare acetazolamide taken the morning of ascent to acetazolamide taken the evening prior to ascent for the prevention of acute mountain sickness (AMS). The day of ascent dosing has not been studied as a powered primary outcome. The study population is hikers who are ascending at their own rate under their own power in a true hiking environment at the White Mountain Research Station, Owen Valley Lab (OVL) and Bancroft Station (BAR), Bancroft Peak, White Mountain, California
Phase:
Phase 1
Details
Lead Sponsor:
Stanford University
Treatments:
Acetazolamide